Amid overdose and suicide crises, SAMHSA has lost more than half its staff.October 30, 2025Check out STAT+Sponsored By Maria Fabrizio for STAT STAT+ | Trump cuts have decimated the federal addiction and mental health agency Trump administration cuts SAMHSA staff by half, terminates $2 billion in grants, during a drug overdose epidemic and a suicide crisis. By O. Rose Broderick and Lev Facher Eli Lilly's weight loss and diabetes drug tops Keytruda as world's best-selling medicine The therapy, marketed as Zepbound and Mounjaro, took the crown from Merck's blockbuster cancer drug at a striking pace. By Elaine Chen STAT+ | Novo Nordisk makes offer for obesity-focused Metsera, aiming to outbid Pfizer Both companies want Metsera's line of experimental weight loss drugs, as pharma firms try to gain an edge in the white-hot market. By Andrew Joseph Mike Reddy for STAT STAT+ | How Moderna, the company that helped save the world, unraveled An in-depth analysis of Moderna's dramatic rise and fall, from mRNA triumph to existential crisis, and what its uncertain future means for biotech. By Jason Mast STAT+ | Biden's law sets Trump up for success in negotiating cheaper Medicare drug prices Trump slams Biden's Medicare drug negotiations but stands to benefit from the Inflation Reduction Act's framework and stronger second-round leverage. By John Wilkerson STAT+ | Opinion: FDA criticism of MDMA-assisted therapy is an opportunity for psychedelic medicine FDA's CRL to Lykos Therapeutics on MDMA therapy for PTSD isn't the end of psychedelic medicine. It's a reset, says Jama Pitman in a STAT First Opinion. By Jama Pitman Molly Ferguson/STAT STAT+ | Biotech might be tiny but the dealmaking is mighty Also this week: A look at Kura and Syndax as they vie for market share among AML patients, and why Intellia faces an existential crisis. By Adam Feuerstein Opinion: Health care workers under 65 must be vaccinated against Covid Health care workers have been overlooked in revised Covid vaccine guidelines, two infectious disease doctors write in a new STAT First Opinion essay. By Judy Stone and Judith Feinberg More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments